Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS

Journal of Molecular Graphics and Modelling

Volumn 28, Issue 5, 2010, Pages 455-463

  Jayakanthan, Mannu ^a   Chandrasekar, Sanniyasi ^a   Muthukumaran, Jayaraman ^a   Mathur, Premendu P ^a  

^a PONDICHERRY UNIVERSITY   (India)

Author keywords

Combination therapy; CYP3A4; HAART; HIV 1 protease drug; Molecular docking; Salvage therapy

Indexed keywords

ANTI-HIV; AUTODOCK; BINDING AFFINITIES; BINDING MODES; COMBINATION THERAPY; CYTOCHROME P450; DRUG BINDING; DRUG-METABOLIZING ENZYMES; HIGHLY ACTIVE ANTI-RETROVIRAL THERAPIES; HIV-1 PROTEASE; HIV-PROTEASE; HIV/AIDS; INFECTED PATIENTS; INTERACTION ENERGIES; ISOFORMS; MOLECULAR DOCKING; OXIDATIVE METABOLISM; POTENTIAL DRUG; PROTEASE INHIBITOR; SALVAGE THERAPY; SAQUINAVIR; SITE DIRECTED MUTAGENESIS; TIPRANAVIR; VIRAL REPLICATION;

AMINO ACIDS; BINDING ENERGY; BINDING SITES; BIOCHEMISTRY; CRYSTALLOGRAPHY; DISEASES; DOCKING; DRUG INTERACTIONS; ENZYME INHIBITION; ENZYMES; METABOLISM; MOLECULAR MODELING; PORPHYRINS; VIRUSES;

DRUG THERAPY;

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 3A4; DARUNAVIR; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROBIC METABOLISM; ARTICLE; COMPUTATIONAL FLUID DYNAMICS; DRUG BINDING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 CYP3A; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; PYRIDINES; PYRIMIDINONES; PYRONES; RITONAVIR; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 71949119264     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2009.10.005     Document Type: Article

References (41)

1. Terwilliger E.F., Sodroski J.G., and Haseltine W.A. Mechanisms of infectivity and replication of HIV-1 and implications for therapy. Ann. Emerg. Med. 19 (1990) 233-241
2. Kozal M.J. Drug-resistant human immunodeficiency virus. Clin. Microbiol. Infect. 15 Suppl. 1 (2009) 69-73
3. Sterne J.A., Hernan M.A., Ledergerber B., Tilling K., Weber R., Sendi P., Rickenbach M., Robins J.M., and Egger M. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 (2005) 378-384
4. Gange S.J., Barron Y., Greenblatt R.M., Anastos K., Minkoff H., Young M., Kovacs A., Cohen M., Meyer W.A., 3rd A., and Munoz. Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J. Epidemiol. Community Health 56 (2002) 153-159
5. Zeldin R.K., and Petruschke R.A. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53 (2004) 4-9
6. Davies D.R. The structure and function of the aspartic proteinases. Annu. Rev. Biophys. Biophys. Chem. 19 (1990) 189-215
7. Brik A., and Wong C.H. HIV-1 protease: mechanism and drug discovery. Org. Biomol. Chem. 1 (2003) 5-14
8. Dickson C., Eisenman R., Fan H., Hunter E., and Teich N. Molecular biology of tumor viruses: RNA tumor viruses. In: Weiss R., Teich N., Varmus H., and Coffin J. (Eds). Protein Biochemistry and Assembly (1982), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 513-548
9. Lambert D.M., Petteway Jr. S.R., McDanal C.E., Hart T.K., Leary J.J., Dreyer G.B., Meek T.D., Bugelski P.J., Bolognesi D.P., Metcalf B.W., et al. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob. Agents Chemother. 36 (1992) 982-988
10. Rose J.R., Babe L.M., and Craik C.S. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69 (1995) 2751-2758
11. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 4686-4690
12. Knox T.A., Oleson L., von Moltke L.L., Kaufman R.C., Wanke C.A., and Greenblatt D.J. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J. Acquir. Immune Defic. Syndr. 49 (2008) 358-368
13. Pham P.A., Hendrix C.W., Barditch-Crovo P., Parsons T., Khan W., Parish M., Radebaugh C., Carson K.A., Pakes G.E., Qaqish R., and Flexner C. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antivir. Ther. 12 (2007) 963-969
14. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J. Acquir. Immune. Defic. Syndr. 34 Suppl. 1 (2003) S91-S94
15. Pfister M., Labbe L., Lu J.F., Hammer S.M., Mellors J., Bennett K.K., Rosenkranz S., and Sheiner L.B. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther. 72 (2002) 133-141
16. Cvetkovic R.S., and Goa K.L. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63 (2003) 769-802
17. Wire M.B., Shelton M.J., and Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45 (2006) 137-168
18. McKeage K., Perry C.M., Keam S.J., and Darunavir:. A review of its use in the management of HIV infection in adults. Drugs 69 (2009) 477-503
19. Busti A.J., Hall R.G., and Margolis D.M. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24 (2004) 1732-1747
20. Sheweita S.A. Drug-metabolizing enzymes: mechanisms and functions. Curr. Drug. Metab. 1 (2000) 107-132
21. Hodgson J. ADMET-turning chemicals into drugs. Nat. Biotechnol. 19 (2001) 722-726
22. Nebert D.W., and Russell D.W. Clinical importance of the cytochrome P450. Lancet 360 (2002) 1155-1162
23. Lynch T., and Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76 (2007) 391-396
24. Yano J.K., Wester M.R., Schoch G.A., Griffin K.J., Stout C.D., and Johnson E.F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J. Biol. Chem. 279 (2004) 38091-38094
25. Williams P.A., Cosme J., Vinkovic D.M., Ward A., Angove H.C., Day P.J., Vonrhein C., Tickle I.J., and Jhoti H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305 (2004) 683-686
26. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34 (2002) 83-448
27. Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V., and Korzekwa K.R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33 (1994) 6450-6455
28. Korzekwa K.R., Krishnamachary N., Shou M., Ogai A., Parise R.A., Rettie A.E., Gonzalez F.J., and Tracy T.S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37 (1998) 4137-4147
29. Kapelyukh Y., Paine M.J., Marechal J.D., Sutcliffe M.J., Wolf C.R., and Roberts G.C. Multiple substrate binding by cytochrome P450 3A4: estimation of the number of bound substrate molecules. Drug Metab. Dispos. 36 (2008) 2136-2144
30. Roussel F., Khan K.K., and Halpert J.R. The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. Arch. Biochem. Biophys. 374 (2000) 269-278
31. Szklarz G.D., and Halpert J.R. Molecular modeling of cytochrome P450 3A4. J. Comput. Aided Mol. Des. 11 (1997) 265-272
32. Marechal J.D., Yu J., Brown S., Kapelioukh I., Rankin E.M., Wolf C.R., Roberts G.C., Paine M.J., and Sutcliffe M.J. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab. Dispos. 34 (2006) 534-538
33. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J. Clin. Pharm. Ther. 23 (1998) 403-416
34. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucleic Acids Res. 28 (2000) 235-242
35. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., and Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34 (2006) D668-D672
36. Jayakanthan M., Wadhwa G., Madhan Mohan T., Arul L., Balasubramanian P., and Sundar D. Computer aided drug design for cancer-causing H-Ras P21 mutant protein. Lett. Drug Des. Discov. 6 (2009) 14-20
37. Gowthaman U., Jayakanthan M., and Sundar D. Molecular docking studies of dithionitrobenzoic acid and its related compounds to protein disulfide isomerase: computational screening of inhibitors to HIV-1 entry. BMC Bioinformatics 9 Suppl. 12 (2008) S14
38. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
39. Arvieux C., and Tribut O. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs 65 (2005) 633-659
40. Mehandru S., and Markowitz M. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert. Opin. Invest. Drugs 12 (2003) 1821-1828
41. Shibata N., Gao W., Okamoto H., Kishida T., Yoshikawa Y., and Takada K. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. J. Pharm. Pharmacol. 54 (2002) 221-229